

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-39. (cancelled)

40. (currently amended) An isolated, substantially purified nucleotide sequence, comprising consisting of SEQ ID NO: 3 and homologous sequences thereof, wherein said homologous sequence exhibits at least 70% homology, wherein said nucleotide sequence is in a screening system and is a marker for compounds exhibiting insulin regulating properties.

41. (cancelled)

42. (cancelled)

43. (previously presented) The nucleotide sequence according to claim 40, wherein said sequence is a marker for thiazolidinedione (TZD) compounds.

44. (previously presented) The nucleotide sequence according to claim 40, wherein said sequence is a marker for adipocyte specific insulin regulating substances.

45. (cancelled)

46. (cancelled)

47. (currently amended) An isolated, substantially purified nucleotide sequence, comprising consisting of SEQ ID

NO:3 and ~~homologous sequences thereof, wherein said homologous sequences exhibit at least 70% homology,~~ wherein said nucleotide sequence is coupled to a reporter system and is a marker for compounds exhibiting insulin regulating properties.

48. (previously presented) The nucleotide sequence according to claim 47, wherein the reported system is a fluorescent reporter molecule.

49. (cancelled)

50. (cancelled)

51. (previously presented) The nucleotide sequence according to claim 47, wherein said sequence is a marker for thiazolidinedione (TZD) compounds.

52. (previously presented) The nucleotide sequence according to claim 47, wherein said sequence is a marker for adipocyte specific insulin regulating substances.

53. (cancelled)

54. (cancelled)

55. (cancelled)